| Autor: |
Abu-Rustum N; Memorial Sloan Kettering Cancer Center., Yashar C; UC San Diego Moores Cancer Center., Arend R; O'Neal Comprehensive Cancer Center at UAB., Barber E; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Bradley K; University of Wisconsin Carbone Cancer Center., Brooks R; UC Davis Comprehensive Cancer Center., Campos SM; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center., Chino J; Duke Cancer Institute., Chon HS; Moffitt Cancer Center., Chu C; Fox Chase Cancer Center., Crispens MA; Vanderbilt-Ingram Cancer Center., Damast S; Yale Cancer Center/Smilow Cancer Hospital., Fisher CM; University of Colorado Cancer Center., Frederick P; Roswell Park Comprehensive Cancer Center., Gaffney DK; Huntsman Cancer Institute at the University of Utah., Giuntoli R; Abramson Cancer Center at the University of Pennsylvania., Han E; City of Hope National Medical Center., Holmes J; Indiana University Melvin and Bren Simon Comprehensive Cancer Center., Howitt BE; Stanford Cancer Institute., Lea J; UT Southwestern Simmons Comprehensive Cancer Center., Mariani A; Mayo Clinic Cancer Center., Mutch D; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Nagel C; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Nekhlyudov L; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center., Podoll M; Vanderbilt-Ingram Cancer Center., Salani R; UCLA Jonsson Comprehensive Cancer Center., Schorge J; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center., Siedel J; University of Michigan Rogel Cancer Center., Sisodia R; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center., Soliman P; The University of Texas MD Anderson Cancer Center., Ueda S; UCSF Helen Diller Family Comprehensive Cancer Center., Urban R; Fred Hutchinson Cancer Center., Wethington SL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Wyse E; Patient advocate., Zanotti K; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., McMillian NR; National Comprehensive Cancer Network., Aggarwal S; National Comprehensive Cancer Network. |
| Abstrakt: |
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org. |
